Acciones de intellia therapeutics inc
17 Jul 2018 Las acciones de las compañías de edición de genes CRISPR Therapeutics AG, Editas Medicine Inc, Sangamo Therapeutics Inc e Intellia 12/5/2019 · Información financiera sobre las acciones de Intellia Therapeutics Inc (NTLA), incluyendo precio de las acciones, último cierre, volumen, variación en 1 año, rango intradía, rango de 52 semanas, capitalización bursátil, ingresos, dividendo etc. de NTLA. 11/28/2019 · Consulta las últimas cotizaciones de acciones, historial, noticias y otra información vital de Intellia Therapeutics, Inc. (NTLA) para ayudarte con tus 8/24/2016 · Las noticias más recientes sobre Intellia Therapeutics Inc y la cotización de las acciones de NTLA en bolsa, última hora y mucho más en Investing.com. Intellia Therapeutics Inc Intellia Therapeutics Inc. (anteriormente conocida como AZRN Inc.) se fundó en 2014 y su sede se ubica en Cambridge, Massachusetts. La empresa se centra actualmente en la edición genética y el desarrollo de terapias basadas en una herramienta biológica única llamada sistema CRISPR/Cas9. 9/8/2010 · Intellia Therapeutics, Inc. is a genome editing company. The Company is focused on developing therapeutics utilizing a biological tool known as
Intellia Therapeutics Inc Intellia Therapeutics Inc. (anteriormente conocida como AZRN Inc.) se fundó en 2014 y su sede se ubica en Cambridge, Massachusetts. La empresa se centra actualmente en la edición genética y el desarrollo de terapias basadas en una herramienta biológica única llamada sistema CRISPR/Cas9.
4/27/2018 · Intellia is rapidly progressing its in vivo data to treat a wide range of liver disease in a relatively short Intellia Therapeutics, Inc. (NTLA) by: Interim Award concluded all technology in dispute was exclusively licensed to Intellia Parties must negotiate terms and payments to Intellia for Caribou’s use of the chemically modified guide RNAs CAMBRIDGE, Mass. , Sept. 26, 2019 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. Intellia Therapeutics, Inc., a genome editing company, focuses on the development of therapeutics utilizing a biological tool known as the CRISPR/Cas9 system. The company develops in vivo programs focused on liver diseases, including transthyretin amyloidosis, alpha-1 antitrypsin deficiency, and primary hyperoxaluria. 10/31/2019 · Find the latest Intellia Therapeutics, Inc. (NTLA) stock quote, history, news and other vital information to help you with your stock trading and investing. 7/31/2019 · And then there's Intellia Therapeutics (NASDAQ:NTLA). The business is valued at $850 million, won't have a drug candidate in clinical trials until 2020 or 2021, and has only named one pipeline asset to date (though it does have a deep-pocketed partner). Intellia Therapeutics, Inc. is a genome editing company. The Company is focused on developing therapeutics utilizing a biological tool known as CRISPR/Cas9. The CRISPR/Cas9 genome editing system includes two components: the Cas9 protein and the guide RNA sequence. View detailed financial information, real-time news, videos, quotes and analysis on Intellia Therapeutics Inc. (NASDAQ:NTLA). Explore commentary on Intellia Therapeutics Inc. and hear what the experts at TheStreet are saying about NTLA.
11/30/2019 · Granahan Investment Management Inc. MA grew its position in Intellia Therapeutics Inc (NASDAQ:NTLA) by 8.2% during the third quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 59,691 shares of the company’s stock after purchasing an additional 4,528 shares during the quarter.
6/19/2017 · Intellia Therapeutics Announces Patent for CRISPR/Cas Genome Editing in China Patent covers CRISPR/Cas9 gene editing methods and compositions for use in any setting, including human and other eukaryotic cells Intellia Therapeutics, Inc. engages in the development of gene editing-based therapies. It provides scientific expertise, clinical development, and intellectual property position to unlock broad therapeutic applications of CRISPR or Cas9 genome editing and develop a potential new drug class. About Intellia Therapeutics Inc Intellia Therapeutics, Inc. engages in the development of gene editing-based therapies. It provides scientific expertise, clinical development, and intellectual property position to unlock broad therapeutic applications of CRISPR or Cas9 genome editing and develop a potential new drug class. 11/30/2019 · Granahan Investment Management Inc. MA grew its position in Intellia Therapeutics Inc (NASDAQ:NTLA) by 8.2% during the third quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 59,691 shares of the company’s stock after purchasing an additional 4,528 shares during the quarter. 12/21/2019 · BlackRock Inc. boosted its stake in Intellia Therapeutics by 6.6% during the 2nd quarter. BlackRock Inc. now owns 3,390,267 shares of the company’s stock worth $55,499,000 after purchasing an additional 208,548 shares during the last quarter. Vanguard Group Inc. boosted its stake in Intellia Therapeutics by 13.2% during the 2nd quarter.
Cotizacion de INTELLIA THERAPEUTICS INC.: datos históricos y INC. 15,38 USD (-2,90%). 27/12/2019 - 12:59 15 minutos de retraso - Acciones NASDAQ
5/13/2019 · Encuentra el debate de accionesIntellia Therapeutics, Inc.(NTLA) más reciente en el foro de Yahoo Finanzas. Comparte tu opinión y gana perspectiva de En el año fiscal que finalizó en 31/12/2018, los ingresos de Intellia Therapeutics Inc increased 16.53% hasta 30.43M. Los ingresos netos decreased 26.35% hasta -85.34M. El patrimonio neto decreased 7.54% hasta 277.92M y los beneficios por acción decreased de -1.88 a -1.98. Intellia Therapeutics, Inc. (NTLA) Shares March Higher, Can It Continue? By Zacks Investment Research - Nov 06, 2019. As of late, it has definitely been a great time to be an investor in Intellia Therapeutics, Inc. (NASDAQ:NTLA) . The stock has moved higher by 22.5% in the past month, while it is also above its 20 Using CRISPR/Cas9 technology, Intellia Therapeutics is developing revolutionary genome editing therapies to cure genetic diseases with simple, targeted treatments.
12/21/2019 · BlackRock Inc. boosted its stake in Intellia Therapeutics by 6.6% during the 2nd quarter. BlackRock Inc. now owns 3,390,267 shares of the company’s stock worth $55,499,000 after purchasing an additional 208,548 shares during the last quarter. Vanguard Group Inc. boosted its stake in Intellia Therapeutics by 13.2% during the 2nd quarter.
Intellia Therapeutics Inc. NTLA Morningstar Rating Rating as of Dec 27, 2019. Quote Stock Analysis News Price vs Fair Value Trailing Returns Financials Intellia Therapeutics Inc. Intellia Therapeutics, Inc. engages in the development of gene editing-based therapies. It provides scientific expertise, clinical development, and intellectual property position to unlock broad therapeutic applications of CRISPR or Cas9 genome editing and develop a potential new drug class. 12/28/2019 · Stock analysis for Intellia Therapeutics Inc (NTLA:NASDAQ GM) including stock price, stock chart, company news, key statistics, fundamentals and company cotización Intellia Therapeutics y gráficas 0JBU. Gratis precios de la bolsa en tiempo real, y los foros más activos del mercado accionario. Cotización Intellia Therapeutics (0JBU), gráficas, operaciones, ranking de las acciones, índices, blogs y foros más populares de la BMV y mucho más. 2/26/2019 · Consulta estimaciones de analistas de acciones de Intellia Therapeutics, Inc. (NTLA), como ingresos y beneficios, beneficios por acción, mejoras y rebajas.
2/26/2019 · Consulta estimaciones de analistas de acciones de Intellia Therapeutics, Inc. (NTLA), como ingresos y beneficios, beneficios por acción, mejoras y rebajas.